InVivo Analytics

Overview

InVivo Analytics is a software company listed in the New York City AI scene[1] that automates segmentation and analysis of medical imaging data from CT, MRI, PET, and optical scans to extract radiomic biomarkers for drug discovery and research[2]. The company was founded in 2014 by Alexander Klose and Neal Paragas[4] and operates as an all-remote organization[9]. InVivo Analytics offers plug-in modules including BLT (Bioluminescence Tomography), BLI (Bioluminescence Imaging), and PET/CT[5]. The platform has been adopted by customers including researchers at Pfizer Drug Safety R&D, Boston University's National Emerging Infectious Diseases Laboratories, and the University of Washington imaging core facility[6]. The company has received NIH SBIR support, including a Phase 2 award and a Fast-track Phase 1/2 award both in August 2025[8].

InVivo Analytics states it was founded in 2014 by Alexander Klose and Neal Paragas. [4]

Business address: 423 W 127th St, New York, New York, 10027. [10]

Customers

InVivo Analytics features testimonials from Ziyue Karen Jiang of Pfizer Drug Safety R&D, Florian Douam of Boston University's National Emerging Infectious Diseases Laboratories, and the University of Washington imaging core facility. [6]

Growth & traction

InVivo Analytics claims its platform is "100x Faster" and "5x Cheaper per subject than CROs." [7]

InVivo Analytics describes itself as "an all-remote company" and lists Neal Paragas, PhD as Co-Founder & CEO, Alexander Klose, PhD as Co-Founder & CTO, Ken Li as Director of Mechanical Engineering and Jay Whalen as Director of Systems Engineering. [9]

Funding history

InVivo Analytics cites NIH SBIR support, including a Phase 2 award in August 2025 and a Fast-track Phase 1/2 award in August 2025. [8]